规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
Smurf1(Kd= 3.664 nM)
|
---|---|
体外研究 (In Vitro) |
在 β-淀粉酶刺激的 RAW264.7 细胞中,Smurf1-IN-A01(10 μM,30-60 分钟)泡沫状 c 型凝集素受体 2d 介导的 MyD88 降解 [1]。在 C3H10T1/2 细胞中,Smurf1-IN-A01(10 μM,24 小时)可降低 ALP 活性并增加茜素红染色 [2]。在 MCF-7 和 T47D 细胞中,Smurf1-IN-A01(10 μM,12 小时)可降低 ERα 蛋白和 ERE 荧光素酶活性 [3]。
|
体内研究 (In Vivo) |
在变性模型中,Smurf1-IN-A01(10 μM、2 μL、玻璃体内显微注射、单体用药)可以放大早期损伤[4]。
|
动物实验 |
Animal/Disease Models: Retinal degeneration model mouse [4]
Doses: 10 μM, 2μL Route of Administration: Injection into the vitreous cavity through a micro syringe. Experimental Results: Reduction of drusen-like spots. Resulting in a wider and straighter outer core layer. Resulting in the disappearance of the inner and outer segment hinges of photoreceptor cells. Downregulates NLRP3 and inhibits IL-1β. Can reduce NaIO3 retinal death. |
参考文献 |
[1]. Li F, et al. C-type lectin receptor 2d forms homodimers and heterodimers with TLR2 to negatively regulate IRF5-mediated antifungal immunity [J]. Nature Communications, 2023, 14(1): 6718.
[2]. Qu M, et al. HSP90β chaperoning SMURF1-mediated LATS proteasomal degradation in the regulation of bone formation [J]. Cellular Signalling, 2023, 102: 110523. [3]. Yang H, et al. SMURF1 facilitates estrogen receptor ɑ signaling in breast cancer cells [J]. Journal of experimental & clinical cancer research, 2018, 37(1): 1-12. [4]. Li D, et al. Smurf1: A possible therapeutic target in dry age-related macular degeneration [J]. Experimental Eye Research, 2023, 233: 109549. [5]. Cao Y, et al. Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. Sci Rep. 2014 May 14;4:4965. |
分子式 |
C22H20CLF3N4O3S
|
---|---|
分子量 |
512.932413101196
|
精确质量 |
512.09
|
元素分析 |
C, 51.52; H, 3.93; Cl, 6.91; F, 11.11; N, 10.92; O, 9.36; S, 6.25
|
CAS号 |
1007647-73-5
|
外观&性状 |
Solid powder
|
SMILES |
O=C(N1CCN(S(=O)(C2=CC=C(Cl)C(C(F)(F)F)=C2)=O)CC1)C3=CC=C(N4N=CC=C4C)C=C3
|
InChi Key |
QFYLTUDRXBNZFQ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H20ClF3N4O3S/c1-15-8-9-27-30(15)17-4-2-16(3-5-17)21(31)28-10-12-29(13-11-28)34(32,33)18-6-7-20(23)19(14-18)22(24,25)26/h2-9,14H,10-13H2,1H3
|
化学名 |
[4-[[4-Chloro-3-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl][4-(5-methyl-1H-pyrazol-1-yl)phenyl]-methanone
|
别名 |
Smurf1 inhibitor A01; Smurf1-IN-A01; Smurf1-inhibitor-A01; Smurf1INA01; Smurf1 IN A01;
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO : 62.5~100 mg/mL ( 121.85~194.95 mM )
|
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9496 mL | 9.7479 mL | 19.4958 mL | |
5 mM | 0.3899 mL | 1.9496 mL | 3.8992 mL | |
10 mM | 0.1950 mL | 0.9748 mL | 1.9496 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Primary selection of potential bio-active compounds.(a) Determination of the efficacy of various selected compounds of enhancing BMP induced ALP activity.(b) Chemical structures of A01 and A17.Sci Rep.2014 May 14;4:4965. th> |
---|
Selective compounds stabilize Smad1/5 protein level.Sci Rep.2014 May 14;4:4965. td> |
Selective compounds impair Smurf1-mediated Smad1/5 degradation.Sci Rep.2014 May 14;4:4965. td> |
Selective compounds enhance BMP-2 signaling responsiveness. Predicted binding modes of selective compounds to the defined pocket.Sci Rep.2014 May 14;4:4965. th> |
---|
Selective compounds potentiate BMP-2 induced osteoblastic activity.Sci Rep.2014 May 14;4:4965. td> |
Binding pocket definition andin silicoscreening.a) Refined structure of the Smurf1 WW1 domain bound to the diphosphorylated (pS210/pS214) region of the Smad1 linker. (b) Refined structure of the Smurf1 WW1 domain bound to the monophosphorylated (pS214) region of the Smad1 linker. (c) Receptor model of the Smurf1 WW1 domain (multiple colored) and diphosphorylated (pS210/pS214) region of the Smad1 linker (yellow). (d) Workflow ofin silicoscreening. td> |